ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
IPO Year:
Exchange: NASDAQ
Website: arcabio.com
ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), (the "Company") a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board of directors (the "Board") of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, the Company explored potential strategic alterna
WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced completion of the merger with Oruka Therapeutics, Inc. ("Oruka") following ARCA's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders on August 22, 2024. ARCA following the merger is referred to herein as the "combined company." As previously announced, the combined company will effect a reverse stock split of its common stock subsequent to the merger. Thomas A. Keuer, President of ARCA said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for the merger with
WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced an update to the previously announced final amount of the special cash dividend (the "Special Dividend"), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka"), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The exact amount of the Special
WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol "ORKA" following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the "Merger"), with a new CUSIP number 687604108 and ISIN number US6876041087. The reverse stock split was approved by ARCA's stockholders at ARCA's special meeting of
Special dividend estimated to be $1.59 per share Payment of special dividend conditioned upon ARCA stockholder approval of the Proposed Merger with Oruka WESTMINSTER, Colo., Aug. 16, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors has declared a special cash dividend (the "Special Dividend") in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka") pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The Special Dividend, which ARCA estimates will be $1.59 per share of ARCA's common stock, will be payable in cash to th
WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), (the "Company") a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board of directors (the "Board") of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, the Company explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. The C
ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), (the "Company") a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board of directors (the "Board") of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, the Company explored potential strategic alterna
Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025 Pre-closing private financing of approximately $275 million anticipated to fund operations through 2027 Companies to hold conference call on April 3, 2024 at 8:30 AM EDT WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO)
Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025 Pre-closing private financing of approximately $275 million anticipated to fund operations through 2027 Companies to hold conference call on April 3, 2024 at 8:30 AM EDT WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARC
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2023 financial results and provided a corporate update. In April 2022, the Board of Directors established a Special Committee (the "Special Committee") and, in May 2022, retained Ladenburg Thalmann & Co. Inc. ("Ladenburg") to evaluate strategic options, including transactions involving a merger, s
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Oct. 18, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Directors established a Special Committee and, in May 2022, retained Ladenburg Thalmann & Co. Inc. ("Ladenburg") to evaluate strategic options, including transactions involving a merger, sale of all o
WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced completion of the merger with Oruka Therapeutics, Inc. ("Oruka") following ARCA's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders on August 22, 2024. ARCA following the merger is referred to herein as the "combined company." As previously announced, the combined company will effect a reverse stock split of its common stock subsequent to the merger. Thomas A. Keuer, President of ARCA said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for the merger with
WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced an update to the previously announced final amount of the special cash dividend (the "Special Dividend"), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka"), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The exact amount of the Special
WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol "ORKA" following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the "Merger"), with a new CUSIP number 687604108 and ISIN number US6876041087. The reverse stock split was approved by ARCA's stockholders at ARCA's special meeting of
Special dividend estimated to be $1.59 per share Payment of special dividend conditioned upon ARCA stockholder approval of the Proposed Merger with Oruka WESTMINSTER, Colo., Aug. 16, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors has declared a special cash dividend (the "Special Dividend") in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka") pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The Special Dividend, which ARCA estimates will be $1.59 per share of ARCA's common stock, will be payable in cash to th
WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), (the "Company") a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board of directors (the "Board") of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, the Company explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. The C
Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025 Pre-closing private financing of approximately $275 million anticipated to fund operations through 2027 Companies to hold conference call on April 3, 2024 at 8:30 AM EDT WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO)
Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025 Pre-closing private financing of approximately $275 million anticipated to fund operations through 2027 Companies to hold conference call on April 3, 2024 at 8:30 AM EDT WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARC
SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)
SC 13D - Oruka Therapeutics, Inc. (0000907654) (Subject)
SC 13G - ARCA biopharma, Inc. (0000907654) (Subject)
SC 13G - ARCA biopharma, Inc. (0000907654) (Subject)
SC 13G - ARCA biopharma, Inc. (0000907654) (Subject)
SC 13G/A - ARCA biopharma, Inc. (0000907654) (Subject)
SC 13D - ARCA biopharma, Inc. (0000907654) (Subject)
SC 13G/A - ARCA biopharma, Inc. (0000907654) (Subject)
SC 13G - ARCA biopharma, Inc. (0000907654) (Subject)
SC 13G/A - ARCA biopharma, Inc. (0000907654) (Subject)
8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
425 - ARCA biopharma, Inc. (0000907654) (Subject)
8-K - ARCA biopharma, Inc. (0000907654) (Filer)
8-K - ARCA biopharma, Inc. (0000907654) (Filer)
425 - ARCA biopharma, Inc. (0000907654) (Subject)
8-K - ARCA biopharma, Inc. (0000907654) (Filer)
425 - ARCA biopharma, Inc. (0000907654) (Subject)
8-K - ARCA biopharma, Inc. (0000907654) (Filer)
425 - ARCA biopharma, Inc. (0000907654) (Subject)
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
The Dow Jones index closed higher by more than 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. ARCA biopharma The Trade: ARCA biopharma, Inc. (NASDAQ:ABIO) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd bought a total of 408,777 shares at an average price of $3.49. To acquire these shares, it cost around $1.4 million. W
Gainers Calidi Biotherapeutics (AMEX:CLDI) shares rose 29.7% to $0.25 during Monday's pre-market session. The market value of their outstanding shares is at $16.0 million. Entero Therapeutics (NASDAQ:ENTO) shares rose 22.41% to $2.99. The company's market cap stands at $8.2 million. TransCode Therapeutics (NASDAQ:RNAZ) stock increased by 19.09% to $1.31. The company's market cap stands at $8.6 million. Brainstorm Cell (NASDAQ:BCLI) shares moved upwards by 15.3% to $0.47. The market value of their outstanding shares is at $33.2 million. CERo Therapeutics Hldgs (NASDAQ:CERO) shares moved upwards by 15.12% to $0.78. The company's market cap stands at $11.6 million. Co-Diagnostics (NASDAQ:
Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 70.4% to $3.51 during Monday's pre-market session. The market value of their outstanding shares is at $5.8 million. Molecular Partners (NASDAQ:MOLN) shares moved upwards by 21.72% to $4.38. The company's market cap stands at $144.0 million. Structure Therapeutics (NASDAQ:GPCR) shares moved upwards by 19.23% to $40.78. The company's market cap stands at $1.9 billion. NewGenIvf Group (NASDAQ:NIVF) stock rose 16.78% to $1.6. The company's market cap stands at $16.2 million. Kyverna Therapeutics (NASDAQ:KYTX) shares increased by 16.6% to $14.61. The market value of their outstanding shares is at $629.9 million. ARCA biopharma (NAS
Gainers Akanda (NASDAQ:AKAN) shares increased by 103.8% to $0.27 during Friday's regular session. The company's market cap stands at $8.6 million. NovaBay Pharmaceuticals (AMEX:NBY) shares rose 48.66% to $0.18. The company's market cap stands at $6.7 million. Pasithea Therapeutics (NASDAQ:KTTA) stock increased by 29.77% to $8.63. The company's market cap stands at $8.9 million. As per the news, the Q1 earnings report came out 3 days ago. TransCode Therapeutics (NASDAQ:RNAZ) stock moved upwards by 27.23% to $1.13. The market value of their outstanding shares is at $6.8 million. Onconetix (NASDAQ:ONCO) stock increased by 26.73% to $0.18. The market value of their outstanding shares is at
Several stocks with high short interest rallied on Monday following an incredible surge in GameStop Corp (NYSE:GME) shares. Here’s a quick look at what you need to know. What To Know: The madness in meme stocks on Monday can be traced back to a social media post from Keith Gill, best known as "Roaring Kitty" on YouTube and X or "DeepF***ingValue" on Reddit. Following three years of silence, Gill took to X over the weekend, posting a meme of a sketched person leaning forward in a chair. GameStop shares more than doubled in Monday’s session before pulling back. The stock still closed up nearly 75% for the day. Several names with high short interest ripped higher in the wake of the Gam
ARCA biopharma (NASDAQ:ABIO) reported quarterly losses of $(0.14) per share. This is a 55.56 percent decrease over losses of $(0.09) per share from the same period last year.
- SEC Filing
Shares of STAAR Surgical Company (NASDAQ:STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3% to $44.30 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares climbed 130.1% to $2.9790. TCBP announced execution of non-binding letter of intent for acquisition of NK Platform Technologies. Allurion Technologies Inc. (NASDAQ:ALUR) gained 70% to $2.8801 after the company announced the commercial availability of its Virtual Care Suite in the United States. Also, Chardan Capital initiated coverage on the stock w
Shares of Flora Growth Corp. (NASDAQ:FLGC) fell sharply in today’s pre-market trading after the company reported the launch of proposed underwritten public offering of common shares. Flora Growth shares tumbled 20.2% to $2.13 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers HWH International Inc. (NASDAQ:HWH) rose 175% to $4.32 in pre-market trading. Zhongchao Inc. (NASDAQ:ZCMD) gained 43% to $2.18 in pre-market trading after gaining 22% on Wednesday. Brooge Energy Limited (NASDAQ:BROG) gained 26.4% to $2.39 in pre-market trading after dipping over 20% on Wednesday. Sintx Technologies, Inc. (NASDAQ:SINT) shares rose 23.5% to $0.0284 in pre-ma
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 0.3% on Wednesday. The Dow traded up 0.08% to 39,200.08 while the NASDAQ rose 0.46% to 16,315.68. The S&P 500 also rose, gaining, 0.31% to 5,221.70. Check This Out: Insiders Buying Walgreens And 2 Other Stocks Leading and Lagging Sectors Industrials shares jumped by 0.8% on Wednesday. In trading on Wednesday, consumer staples shares fell by 0.9%. Top Headline Acuity Brands, Inc (NYSE:AYI) reported better-than-expected earnings for its second quarter. The company posted a quarterly net sales decline of 4.0% year-over-year to $905.9 million, missing the consensus of $907.7 million. It cloc